{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T10:50:43Z","timestamp":1768906243182,"version":"3.49.0"},"reference-count":53,"publisher":"Japanese Pharmacological Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2010]]},"DOI":"10.1254\/jphs.09355fp","type":"journal-article","created":{"date-parts":[[2010,5,19]],"date-time":"2010-05-19T02:30:19Z","timestamp":1274236219000},"page":"134-142","source":"Crossref","is-referenced-by-count":20,"title":["Effect of an Herbal Preparation, STW 5, in an Acute Model of Reflux Oesophagitis in Rats"],"prefix":"10.1254","volume":"113","author":[{"given":"Heba","family":"Abdel-Aziz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala F.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried","family":"Neuhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"Kelber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dieter","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed T.","family":"Khayyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710\u2013717.","DOI":"10.1136\/gut.2004.051821"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Boeckxstaens GE. Emerging drugs for gastro-oesophageal reflux disease. Expert Opin Emerg Drugs. 2009;14:481\u2013491.","DOI":"10.1517\/14728210903133807"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Ali T, Roberts DN, Tierney WM. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122:896\u2013903.","DOI":"10.1016\/j.amjmed.2009.04.014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Malfertheiner P, Hallerback B. Clinical manifestations and complications of gastrooesophageal reflux disease (GERD). Int J Clin Pract. 2005;59:346\u2013355.","DOI":"10.1111\/j.1742-1241.2005.00370.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Pereira Rde S. Regression of gastro-esophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and amino acids: comparison with omeprazole. J Pineal Res. 2006;41:195\u2013200.","DOI":"10.1111\/j.1600-079X.2006.00359.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Azpiroz F, Bouin M, Camilleri M, Mayer EA, Poitras P, Serra J, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil. 2007;19:62\u201368.","DOI":"10.1111\/j.1365-2982.2006.00875.x"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, et al. Gastro-oesophageal reflux might cause oesophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology. 2009;137:1776\u20131784.","DOI":"10.1053\/j.gastro.2009.07.055"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kindt S, Tertychnyy A, de Hertogh G, Geboes K, Tack J. Intestinal immune activation in presumed post-infectious functional dyspepsia. Neurogastroenterol Motil. 2009;21:832\u2013856.","DOI":"10.1111\/j.1365-2982.2009.01299.x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Nastaskin I, Mehdikhani E, Conklin J, Park S, Pimentel M. Studying the overlap between IBS and GERD: a systematic review of the literature. Dig Dis Sci. 2006;51:2113\u20132120.","DOI":"10.1007\/s10620-006-9306-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Quigley EMM, Keohane J. Dyspepsia. Curr Opin Gastroenterol. 2008;24:692\u2013697.","DOI":"10.1097\/MOG.0b013e328313b983"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Saad RJ, Chey WD. Review article: current and emerging therapies for functional dyspepsia. Aliment Pharmacol Ther. 2006;24:475\u2013492.","DOI":"10.1111\/j.1365-2036.2006.03005.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Stanghellini V, Barbara G, Cogliandro R, Salvioli B, Cremon C, de Giorgio R, et al. Overlap between GERD and IBS: irrefutable but subtle. J Clin Gastroenterol. 2007;41:S114\u2013S117.","DOI":"10.1097\/MCG.0b013e31803d0f94"},{"key":"13","unstructured":"13 Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord. 2006;6:72\u201378."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kroll U, Cordes C. Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine. 2006;13:SV12\u2013SV19.","DOI":"10.1016\/j.phymed.2006.03.016"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogasts). Phytomedicine. 2006;13:SV20\u2013SV35.","DOI":"10.1016\/j.phymed.2006.07.001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Allescher HD, Wagner H. STW 5\/Iberogast: multi-target-action for treatment of functional dyspepsia and irritable bowel syndrome. Wien Med Wochenschr. 2007;157:301\u2013307.","DOI":"10.1007\/s10354-007-0429-3"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Gundermann KJ, Godehardt E, Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials. Adv Ther. 2003;20:43\u201349.","DOI":"10.1007\/BF02850118"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Madisch A, Holtmann G, Mayr G, Vinson B, Hotz J. Treatment of functional dyspepsia with a herbal preparation. A double-blind, randomized, placebo-controlled, multicenter trial. Digestion. 2004;469:45\u201352.","DOI":"10.1159\/000076546"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther. 2004;19:271\u2013279.","DOI":"10.1111\/j.1365-2036.2004.01859.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Madisch A, von Arnim U, M\u00fcller J, Vinson B, Zeller K, Malfertheiner P. Herbal preparation STW 5 improved quality of life in patients with functional dyspepsia \u2013 results of a placebo-controlled trial. Gastroenterology. 2008;134:A422.","DOI":"10.1016\/S0016-5085(08)61973-3"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 R\u00f6sch W, Vinson B, Sassin I. A randomized clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol. 2002;40:401\u2013408.","DOI":"10.1055\/s-2002-32130"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 R\u00f6sch W, Liebregts T, Gundermann KJ, Vinson B, Holtmann G. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5. Phytomedicine. 2006;13:SV114\u2013SV121.","DOI":"10.1016\/j.phymed.2006.03.022"},{"key":"23","unstructured":"23 Khayyal MT, El-Ghazaly MA, Kenawy SA, Seif-el-Nasr M, Mahran LG, Kafafi YA, et al. Antiulcerogenic effect of some gastrointestinal acting plant extracts and their combination. Arzneimittelforschung. 2001;51:545\u2013553."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA, Okpanyi SN, Kelber O, Weiser D. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound acidity. Phytomedicine. 2006;13:SV56\u2013SV66.","DOI":"10.1016\/j.phymed.2006.03.019"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Hohenester B, R\u00fchl A, Kelber O, Schemann M. The herbal preparation STW 5 (lberogast) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil. 2004;16:765\u2013773.","DOI":"10.1111\/j.1365-2982.2004.00548.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol. 2004;102:1276\u20131283.","DOI":"10.1111\/j.1572-0241.2007.01142.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Liu CY, M\u00fcller MH, Glatzle J, Weiser D, Kelber O, Enck P, et al. The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil. 2004;16:759\u2013764.","DOI":"10.1111\/j.1365-2982.2004.00576.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 M\u00fcller MH, Liu CY, Glatzle J, Weiser D, Kelber O, Enck P, et al. STW 5 (Iberogast) reduces afferent sensitivity in the rat small intestine. Phytomedicine. 2006;13:SV100\u2013SV106.","DOI":"10.1016\/j.phymed.2006.03.014"},{"key":"29","unstructured":"29 Schemann M, Kr\u00fcger D, Gruber L, Angay O, Rohn M, Zeller F, et al. Action profile of the phytomedicine STW 5 suggests novel indications. Neurogastroenterol Motil. 2008;20:S95."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Kahrilas PJ. GERD pathogenesis, pathophysiology, and clinical manifestations. Cleve Clin J Med. 2003;70:S4\u2013S19.","DOI":"10.3949\/ccjm.70.Suppl_5.S4"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Yamato M, Nagahama K, Kotani T, Kato S, Takeuchi K. Biphasic effect of Prostaglandin E<SUB>2<\/SUB> in a rat model of oesophagitis mediated by EP1 receptors: relation to pepsin secretion. Digestion. 2005;72:109\u2013118.","DOI":"10.1159\/000088365"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Uchiyama M, Mihara M. Determination of malondialdehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86:271\u2013278.","DOI":"10.1016\/0003-2697(78)90342-1"},{"key":"33","unstructured":"33 Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344\u20131350."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086\u20132100.","DOI":"10.1016\/S0140-6736(06)68932-0"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Chapman DB, Rees CJ, Lippert D, Sataloff RT, Wright SC Jr. Adverse effects of long-term proton pump inhibitor use: a review for the otolaryngologist. J Voice. 2010 (in press).","DOI":"10.1016\/j.jvoice.2009.10.015"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Reimer C, S\u00f8ndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80\u201387.","DOI":"10.1053\/j.gastro.2009.03.058"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol. 2006;62:473\u2013479.","DOI":"10.1007\/s00228-006-0131-1"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Fournier MR, Targownik LE, Leslie WD. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures. Maturitas. 2009;64:9\u201313.","DOI":"10.1016\/j.maturitas.2009.07.006"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Talley NJ. Risks of proton-pump inhibitors: what every doctor should know. Med J Aust. 2009;190:109\u2013110.","DOI":"10.5694\/j.1326-5377.2009.tb02305.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Madisch A, Mueller MH, Vinson B, Weiser D. Herbal preparation STW 5 significantly improved concomitant reflux symptoms in patients with functional dyspepsia \u2013 a subgroup analysis of placebo-controlled trials. Gastroenterology. 2008;134:A422.","DOI":"10.1016\/S0016-5085(08)61974-5"},{"key":"41","unstructured":"41 Yamaguchi T, Yoshida N, Tomatsuri N, Takayama R, Katada K, Takagi T, et al. Cytokine-induced neutrophil accumulation in the pathogenesis of acute reflux oesophagitis in rats. Int J Mol Med. 2005;16:71\u201377."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Shin YK, Sohn UD, Choi MS, Kum C, Sim SS, Lee MY. Effects of rutin and harmaline on rat reflux oesophagitis. Auton Autacoid Pharmacol. 2002;22:47\u201355.","DOI":"10.1046\/j.1474-8673.2002.00241.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Olyaee M, Sontag S, Salman W, Schnell T, Mobarhan S, Eiznhamer D, et al. Mucosal reactive oxygen species production in oesophagitis and Barrett\u2019s oesophagus. Gut. 1995;37:168\u2013173.","DOI":"10.1136\/gut.37.2.168"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Wetscher GJ, Hinder RA, Klingler P, Gadenst\u00e4tter M, Perdikis G, Hinder PR. Reflux oesophagitis in humans is a free radical event. Dis Oesophagus. 1997;10:29\u201332.","DOI":"10.1093\/dote\/10.1.29"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Schempp H, Weiser D, Kelber O, Elstner EF. Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast) and its components. Phytomedicine. 2006;13:SV36\u2013SV44.","DOI":"10.1016\/j.phymed.2006.03.017"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Germann I, Hagelauer D, Kelber O, Vinson B, Laufer S, Weiser D, et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast). Phytomedicine. 2006;13:SV45\u2013SV50.","DOI":"10.1016\/j.phymed.2006.03.018"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. 2004;96:229\u2013245.","DOI":"10.1254\/jphs.CRJ04003X"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Rao CV, Vijayakumar M. Effect of quercetin, flavonoids and \u03b1-tocopherol, an antioxidant vitamin on experimental reflux oesophagitis in rats. Eur J Pharmacol. 2008;589:233\u2013238.","DOI":"10.1016\/j.ejphar.2008.04.062"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Bonaterra GA, Kelber O, Kinscherf R, Traut U, Seitz S, Weiser D, et al. Anti-inflammatory and anti-cancer effects of the phytomedicine STW 5 and its components in vitro. Planta Med. 2008;74:PA295.","DOI":"10.1055\/s-0028-1084293"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 O\u2019Riordan JM, Abdel-latif MM, Ravi N, McNamara D, Byrne PJ, McDonald GS, et al. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol. 2005;100:1257\u20131264.","DOI":"10.1111\/j.1572-0241.2005.41338.x"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Colleypriest BJ, Ward SG, Tosh D. How does inflammation cause Barrett\u2019s metaplasia? Curr Opin Pharmacol. 2009;9:721\u2013726.","DOI":"10.1016\/j.coph.2009.09.005"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Abdel-Latif MM, O\u2019Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett\u2019s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239:491\u2013500.","DOI":"10.1097\/01.sla.0000118751.95179.c6"},{"key":"53","unstructured":"53 Nieber K, Michael S, Vinson B, Kelber O. Anti-inflammatory pathways involved in the multi-target action of STW5 (Iberogast<SUP>&#174;<\/SUP>). Neurogastroenterol Motil. 2009;21:S77\u2013S78."}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:06:58Z","timestamp":1621436818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/113\/2\/113_09355FP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.09355fp","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}